Search
Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23
- blonca9
- Nov 3, 2023
- 1 min read
Steven Kelly describes how Carisma is leveraging Moderna's mRNA and LNP expertise to engineer monocytes in-vivo to act as a cell therapy against cancer.